Liptruzet Side Effects
Generic name: atorvastatin / ezetimibe
Medically reviewed by Drugs.com. Last updated on May 1, 2022.
Note: This document contains side effect information about atorvastatin / ezetimibe. Some of the dosage forms listed on this page may not apply to the brand name Liptruzet.
Applies to atorvastatin/ezetimibe: oral tablet
General
The more commonly reported adverse reactions have included increased ALT, increased AST, and musculoskeletal pain.[Ref]
Hepatic
Common (1% to 10%): ALT increased (5%), AST increased (4%)
Postmarketing reports: Hepatitis, cholelithiasis, cholecystitis, fatal and nonfatal hepatic failure[Ref]
Musculoskeletal
Common (1% to 10%): Musculoskeletal pain (3.8 to 4%), arthralgia (3 to 6.9%), pain in extremity (2.7 to 6%), myalgia (3.5%), muscle spasms (3%), muscle weakness (2%)
Postmarketing reports: Myopathy/rhabdomyolysis, necrotizing myopathy (rarely), injury, poisoning and procedural complication, tendon rupture, myositis[Ref]
Gastrointestinal
Common (1% to 10%): Diarrhea (4.1 to 6.8%), abdominal pain (3%), nausea (3 to 4%), dyspepsia (4.7%)[Ref]
Nervous system
Common (1% to 10%): Dizziness (2 to 6%), insomnia (3%), fatigue (2.4%)
Postmarketing reports: Headache, paraesthesia, peripheral neuropathy, amnesia, memory impairment, confusion, depression, dizziness[Ref]
Metabolic
Common (1% to 10%): Hyperkalemia (2%)[Ref]
Endocrine
Common (1% to 10%): Hot flushes (2%)[Ref]
Genitourinary
Common (1% to 10%): Urinary tract infection (5.7%)[Ref]
Hematologic
Postmarketing reports: Thrombocytopenia, elevated creatine phosphokinase[Ref]
Hypersensitivity
Postmarketing reports: Anaphylaxis, hypersensitivity reactions[Ref]
Immunologic
Common (1% to 10%): Influenza (2%)[Ref]
Respiratory
Common (1% to 10%): Coughing (2 to 3%), bronchitis (2%), sinusitis (2 to 2.8%), upper respiratory tract infection (4.3%), nasopharyngitis (up to 8.3%), pharyngolaryngeal pain (up to 2.3%)
Postmarketing reports: Interstitial lung disease[Ref]
Other
Postmarketing reports: Fatigue
Dermatologic
Postmarketing reports: Angioedema, bullous rashes (including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis), rash, urticaria[Ref]
More about Liptruzet (atorvastatin / ezetimibe)
- Drug interactions
- Dosage information
- During pregnancy
- Imprints, shape & color data
- Drug class: antihyperlipidemic combinations
- FDA approval history
Patient resources
Professional resources
Related treatment guides
References
1. Cerner Multum, Inc. "Australian Product Information." O 0
2. "Product Information. Liptruzet (atorvastatin-ezetimibe)." Merck & Company Inc (2013):
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.